APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact...

APRE APRE Agenzia per la promozione della Agenzia per la promozione della

Ricerca EuropeaRicerca Europea

Caterina Buonocore, Health National Contact Point for Italy,

“Part of this presentation is taken from the official material produced by EC, DG Research, Unit F”.

AGENDA

PRESENTAZIONE APRESETTIMO PROGRAMMA QUADRO (7PQ)

1. Structure and scope of Health theme

2. Basic principles

3. Health 2013 Work programme key features / priorities

4. How to find partners

5. Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH, ENV…

6. Other funding opportunities for health researchers

7. Information sources

[COS’É APRE?][COS’É APRE?]

L' APRE è un Ente di ricerca non profit con obiettivo, sancito dall’articolo 3 del suo statuto, di promuovere la partecipazione italiana ai programmi di ricerca e sviluppo finanziati dalla Commissione Europea.

È sostenuta da numerose Università e organizzazioni private e pubbliche del mondo accademico, dell’industria e della finanza.

[MISSION][MISSION]

[INTERLOCUTORI][INTERLOCUTORI]

Soci APRESoci APRE

[RISORSE APRE – SPORTELLI LOCALI][RISORSE APRE – SPORTELLI LOCALI]

Per rafforzare il sistema della cooperazione tra istituzioni pubbliche e private attive nel settore della ricerca scientifica e tecnologica e

promuovere e diffondere la ricerca europea a livello nazionale, APRE dispone di una rete di Sportelli regionali.

Per rafforzare il sistema della cooperazione tra istituzioni pubbliche e private attive nel settore della ricerca scientifica e tecnologica e

promuovere e diffondere la ricerca europea a livello nazionale, APRE dispone di una rete di Sportelli regionali.

Gli Sportelli, oltre a fornire tutti i servizi specifici dell'APRE, costituiscono anche una sede per favorire le iniziative promosse dai

Soci APRE presenti nella regione, supportando inoltre quelle portate avanti da parte di altre istituzioni ed organizzazioni impegnate nel

campo della ricerca e dell'innovazione tecnologica

Gli Sportelli, oltre a fornire tutti i servizi specifici dell'APRE, costituiscono anche una sede per favorire le iniziative promosse dai

Soci APRE presenti nella regione, supportando inoltre quelle portate avanti da parte di altre istituzioni ed organizzazioni impegnate nel

campo della ricerca e dell'innovazione tecnologica

Ospitati e gestiti dai Soci APRE, gli Sportelli APRE sono punti di accesso alle informazioni ad operatività regionale e coordinati dalla

sede centrale a Roma.

Ospitati e gestiti dai Soci APRE, gli Sportelli APRE sono punti di accesso alle informazioni ad operatività regionale e coordinati dalla

sede centrale a Roma.

[RISORSE APRE – SPORTELLO EUROPA][RISORSE APRE – SPORTELLO EUROPA]

partecipazione ad eventi e giornate informative partecipazione ad eventi e giornate informative

diffusione di informazioni aggiornate sulle politiche, iniziative ed opportunità sulla ricerca in Europa

diffusione di informazioni aggiornate sulle politiche, iniziative ed opportunità sulla ricerca in Europa

collegamento diretto con vari attori della ricerca Europea (Istituzioni Europee, liaison office e organismi di ricerca degli

Stati Membri, Confederazioni e Consorzi paneuropei)

collegamento diretto con vari attori della ricerca Europea (Istituzioni Europee, liaison office e organismi di ricerca degli

Stati Membri, Confederazioni e Consorzi paneuropei)

accompagnamento agli incontri con i funzionari della Commissione Europea

accompagnamento agli incontri con i funzionari della Commissione Europea

la sala riunione per meeting internazionali dei progetti Europei di ricerca

la sala riunione per meeting internazionali dei progetti Europei di ricerca

APRE BRUSSEL offre ai soci:

[MISSION][MISSION]

1

Silvio Garattini (Mario Negri)

Stefano Vella(ISS)

Caterina Buonocore (APRE)

Alfredo Cesario(IRCSS)

PUNTI DI CONTATTO NAZIONALI

Caterina BuonocoreAPRE

Bruno MourenzaAPRE

COMITATO DI PROGRAMMA SALUTE

IN ITALIA:

[MISSION][MISSION]

Proposta vincente

Formazione

InformazioneAssistenza

•Essere un buon coordinatore•Preparazione della proposta•Come disseminare i risultati della ricerca•Proprietà intellettuale e Consortium Agreement

Formazione

•Conferenze•News Alert•Sito web ( www.apre.it) •Pubblicazioni

Informazione

•Identificazione del tema e del topic FP7•Verificare l’elegibilità della proposta•Pre-screening della proposta•Aiuto nell‘utilizzo dell’EPSS System

Supporto prima dell’inizio del

progetto (telefono, mail e incontri)

•Negoziazione•Management del progetto•Disseminazione dei risultati•Reporting

Supporto dopo l’inizio del progetto

(telefono, mail e incontri)

APRE ospita i Punti di contatto nazionale del VII Programma Quadro in Italia. Questi sono nominati dal Ministero dell'Università e della Ricerca (MUR) e riconosciuti dalla Commissione Europea.

http://www.apre.it/

SALUTE NEL 7 PQ

COME SCEGLIERE IL BANDO GIUSTO IN

UN PANORAMA ARTICOLATO

The 7th Framework programme (FP7)


2. Basic principles

3. Health 2013 Work programme key features / priorities4. Identification of opportunities for health researchers under other FP7

themes: KBBE, ICT, NMP, SSH…

5. Other funding opportunities for health researchers

6. Information sources

EU research policy

Why ?

to improve quality of life and to improve competiveness of Europe

through collaboration

How ?

by pooling resources (funds for Framework Programme) by coordinating national research programmes

Interlocutori

Università

PMI

Industria

IRCCS

Ospedali

Centri di ricerca

Ricerca clinica

[INTERLOCUTORI SALUTE][INTERLOCUTORI SALUTE]

Associazioni di pazienti

CooperationCooperation I deasI deas

PeoplePeople CapacitiesCapacities

Joint Research Centre (non-nuclear)

Euratom

JRC

Euratom

+

+

16

FP7

© Fit for Health, 2012

FundamentalResearch

AppliedResearch

DemonstratorPrototype

Product,Service

End-user

ApplicationResearch & Development

Ideas Cooperation Capacities

People

0 5 10 15 20 years

17

R&D Chain

© Fit for Health, 2012

EUROPEAN COMMISSION - Research DG

7th FrameworkProgramme for Research

Indicative breakdown (€ million)

Collaborative research in the Health theme

Budget: €6.1 billion over 7 years (2007-2013)

Main policy drivers:

Improving health of European citizens Increasing competitiveness of European health-related industries and

businesses Addressing global health issues, including emerging epidemics

Collaborative researchacross borders and other barriers between countries:

at least 3 partners from the 27 EU Member States: Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Rumania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom.

or the 12 Associated Countries:Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey.

In addition, researchers from anywhere in the world can participate: eg: Australia, Brazil, Canada, China, Egypt, India, Japan, Korea, Russia, South-Africa, USA, … and in many cases, can be funded.

Collaborative research

across borders and other barriers

between countries

but also: between different types of organizations

Public & private sector: universities, research centres, large companies, small and medium-sized enterprises (SMEs), etc.

between disciplines: multidisciplinary, translational R&D

The Health ThemeThree main activities (“pillars”)

Activity 1:

Biotechnology, generic tools

& technologies for health

Activity 2:

Translating research for

human health

Activity 3:

Optimising the delivery

of health care

cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health

issuesActivity 4: Support actions & response to policy

needs

The Innovative Medicines Initiative

EC Funding Strategy

DiscoveryDiscovery PreclinicalPreclinical Phase I/IIaPhase I/IIa Phase II + IIIPhase II + III RegulatoryRegulatory

EDCTPLarge Collaborative Projects

Research Grants Product development, PPP

Translationalresearch

Clinicalcapacity

Bottlenecks = Innovative Medicine Initiative (IMI)

Policy aspects

Emphasis and special measures for: Small & Medium-sized Enterprises (SMEs)

Opportunities and support measures

International Cooperation

the possibility to tackle issues on a global scale

an opportunity to extend your networks beyond Europe

Industry (esp. SME) participation & International Cooperation

2. Basic Principles

Basic principles:

Annual calls for proposals (2-stage) Evaluation by panels of independent experts overseen by Independent

Observers 3 criteria:

Science & Technology excellence Implementation & Management Potential Impact

Feedback: Evaluation Summary Reports (ESRs)

Submission & evaluation

Experts

wanted !

Aim: to fund the best R&D proposals

3. HEALTH 2013 Work Programme

Funding schemes for these calls

Note: there are some exceptions to the ceilings.

Priorities for Health in 2012-2013

2013 thematic priorities:

Brain research

Anti-microbial resistance

Comparative effectiveness (CER)

Cross-cutting priorities:

Translation of results into applications

Innovation & SMEs

Social innovationSocial innovation refers to new strategies, concepts, ideas and

organizations that meet social needs of all kinds - from working conditions and education to community development and health - and that extend and strengthen civil society.

International cooperation

http://en.wikipedia.org/wiki/Strategies

http://en.wikipedia.org/wiki/Concepts

http://en.wikipedia.org/wiki/Idea

http://en.wikipedia.org/wiki/Organizations

http://en.wikipedia.org/wiki/Social

http://en.wikipedia.org/wiki/Working_condition

http://en.wikipedia.org/wiki/Education

http://en.wikipedia.org/wiki/Community_development

http://en.wikipedia.org/wiki/Health

http://en.wikipedia.org/wiki/Civil_society

• FP7-HEALTH-2013-INNOVATION-1 as main call with an indicative budget of EUR 680 million with broader topics of which many are tailored for SME participation (bottom-up with a minimum percentage of EU funding requested going to SMEs)

• FP7-HEALTH-2013-INNOVATION-2 as a specific call to boost SME participation for innovative solutions in the health sector with an indicative budget of EUR 140 million. This call has very specific conditions. Maximum project duration is limited to 3 years.

HEALTH

2 STAGE EVALUATION. Max 6 pagine:1.1 Concept and objectives1.2 Progress beyond the state-of-the-art1.3 S/T methodology and associated work plan2.1 Expected impacts

Call identifier: FP7-HEALTH-2013-INNOVATION-135 topicsProposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012Deadline for stage 1 proposals: 02 October 2012 at 17:00:00 (Brussels local time)Indicative budget: EUR 680 million from the 2013 budget

7th CALL HEALTH

Call identifier: FP7-HEALTH-2013-INNOVATION-22 topicsProposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012Deadline for stage 1 proposals: 25 September 2012 at 17:00:00 (Brussels local time)Indicative budget: EUR 140 million from the 2013 budget

2013 WP preparationMilestones and meetings

Roadmap discussed at PC meeting: 5 September 2011

Draft WP v1 (“Orientation paper”) => sent to PC by mid-October

Meeting with Advisory Group (9 Nov 2011)

PC meeting (9-10 Nov 2011) to discuss draft WP v1

PC meeting (14 Feb. 2012) to discuss draft WP v2 => final input by 24 February

Internal draft must be ready by 12 March.

Inter-service Consultation (April-May 2012) - draft WP v3

Formal PC consultation (June 2012) - draft WP v4

Work Programme adoption & publication: 10 July 2012

Health themeCross cutting topic relevant to the entire Health theme 0-1 - Boosting the translation of FP projects' results

into innovative applications for health. FP7-Health-2013-

INNOVATION-2 • build on the results of projects funded under Health theme of FP6 & FP7. • focus on specifications, testing and validation of results • applicants must control the IPR to be used in their application

New: SMEs must be from Member States or Associated Countries(conditions specified, further changes to come based on INNOV-2 call)

Funding scheme: CP-FP, max. €6m/project. MS & AC SMEs only.SME-topic: min. 50% EC contribution to SMEs

Indicative budget: €75 million

The Health theme

1: Biotechnology, generic tools and medical for technologies for human health

1.1 High-throughput research (closed)

1.2 Detection, diagnosis and monitoring

1.3 Suitability, safety and efficacy of therapies

1.4 Innovative therapeutic approaches and interventions

Area 1.2 Detection, Diagnosis and Monitoring

Activity 1Biotech, tools & technologies

1.2 – Detection, Diagnosis & Monitoring

1.2-1 - Development of imaging technologies for therapeutic interventions in rare diseases.

Funding scheme:CP-FP, max. €6m/project.SME-topic: min. 30% EC contribution to SMEs

Area 1.3 Suitability, Safety and Efficacy of Medicines


1.3 – Suitability, safety & efficacy of medicines

1.3-1 - Modelling toxic responses in case studies for predictive human safety assessment.

Funding scheme:CP-FP, max. €12m/project.Industry topic: min. 15% EC contribution to industry, incl. SMEs

Only one proposal may be selected

1.3-2 - Innovative approaches to address adverse immune reactions to biomedical devices, implants & transplant tissues.Funding scheme:CP-FP, max. €6m/project.Industry topic: min. 30% EC contribution to industry, incl. SMEs


1.3 – Suitability, safety & efficacy of medicines

1.3-3 - Safety and efficacy of therapeutic vaccines.

Funding scheme:CP-FP, max. €6m/project.Industry topic: min. 30% EC contribution to industry, incl. SMEs

1.3-4 - Development of alternative in vitro, analytical, immunochemical, and other test methods for quality control of vaccines.

Funding scheme:CP-FP, max. €6m/project. New: max. 3 yearsSME topic: min. 30% EC contribution to SMEs

Area 1.4 Innovative therapeutic approaches and interventions


1.4-1 - Controlling differentiation and proliferation in human stem cells intended for therapeutic use.

Funding scheme:CP-FP, max. €6m/project.SME topic: min. 15% EC contribution to SMEs

The Health theme

2: Translating research for human health

2.1 Integrating biological data and processes: large-scale data gathering, systems biology

2.2 Research on the brain and related diseases, human development and ageing

2.3 Translational research in major infectious diseases: to confront major threats to public health

2.4 Translational research in other major diseases

Area 2.1.1 Large-scale data gathering

Activity 2 - Translating research for human health

2.1.1 – Large-scale data gathering

2.1.1-1 - Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes.

Funding scheme:CP-IP, max. €12m/project.SME topic: min. 30% EC contribution to SMEs

2.1.1-2 - High impact research initiative on metagenomics for personalised medicine approaches.

Funding scheme:IP, max. €30m/project; max. 1 projectIndustry topic: min. 30% EC contribution to industry, incl. SMEs

Only one proposal may be selected

Area 2.2.1 Research on the brain and brain related diseases


2.2.1-1 - Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI)

Funding scheme:CP-IP, max. €30m/project, one or more projects

2.2.1-2 - Development of effective imaging tools for diagnosis, monitoring and management of mental disorders

Funding scheme:CP-FP, max. €6m/projectIndustry topic: min. 30% EC contribution to industry, incl. SMEs


2.2.1 – The brain and brain disorders

2.2.1-3 - Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment

Funding scheme:CP-FP, max. €6m/project

SME topic: min. 15% EC contribution to SMEs

2.2.1-4 - Patho-physiology and therapy of epilepsy and epileptiform disorders

Funding scheme:CP-IP, max. €12m/projectSME topic: min. 15% EC contribution to SMEs

2.2.1-5 – Understanding and combating pain (NEW)

Funding scheme:CP-FP, max. €6m/project

Area 2.3 Translational research in major infectious diseases; to confront major threats to public health

2.3.0 – Cross cutting issues2.3.1 – Antimicrobial drug resistance2.3.2 – HIV/AIDS, malaria, tuberculosis (closed)2.3.3 – Potentially new & re-emerging epidemics2.3.4 – Neglected infectious diseases


2.3.0 – Cross-cutting priorities

2.3.0-1 – Innovation in vaccines

Funding scheme:CP-FP, max. €6m/project.SME topic: min. 30% EC contribution to SMEs


2.3.1 – Anti-microbial drug resistance

2.3.1-2 - Stratified approaches to antibacterial and/or antifungal treatment

Funding scheme:CP-FP, max. €6m/project.

2.3.1-1 – INNOVATION 2 Drugs and vaccines for infections that have developed or are at risk of developing significant antimicrobial resistance.New: SMEs must be from Member States or Associated CountriesFunding scheme:CP-FP, max. €6m/project. MS & AC SMEs only.



2.3.3 – Potentially new and re-emerging epidemics

2.3.3-1 – Clinical management of patients in severe epidemics.

Funding scheme: IP, max. €24m/project; max. 1 project


2.3.4 – Neglected infectious diseases

2.3.4-1 – Neglected infectious diseases of Central and Eastern Europe.

Funding scheme: FP, max. €6m/project.SME topic: min. 15% EC contribution to

SMEs

2.3.4-2 – Drug development for neglected parasitic diseases.

Funding scheme:FP, max. €3m/project.

Area 2.4 Translational researchin other major diseases 2.4.1 – Cancer

2.4.2 – CVD2.4.3 – Diabetes/obesity (closed)2.4.4 – Rare diseases (closed)2.4.5 – Chronic diseases (closed)

Activity 2 - Translating research for human health2.4.1 – Cancer

2.4.1-1 – Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer.


2.4.1-2 – Strengthening the cancer patient's immune system.


Industry topic: min. 30% EC contribution to industry, incl. SMEs

2.4.1-3 - Investigator-driven supportive and palliative care clinical trials and observational studies.



2.4.2 – Cardiovascular diseases2.4.2-1 – Discovery research to reveal novel targets for

cardiovascular disease treatment.Funding scheme:CP-FP, max. €6m/project.


2.4.2-2 – Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases.


2.4.2-3: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan.

Funding scheme:CP-FP, Small €3m/project.

The Health Theme

3: Optimising the delivery of healthcare to European citizens

3.1 Translating clinical research into clinical practice

3.2 Quality, efficiency and solidarity of healthcare systems (closed)

3.3 Health promotion and prevention

3.4 International public health & health systems (closed)

Activity 3 Optimising the delivery of healthcare

3.1 – Translating clinical research into clinical practice

3.1-1 - Comparative Effectiveness Research (CER) in health systems and health services interventions.


3.3 – Health promotion and prevention

3.3-1 - Social innovation for health promotion

Funding scheme: CP-FP, max. €6m/project.SME topic: min. 15% EC contribution to

SMEs

The Health theme

4: Actions across the Theme

4.1 Coordination & Support Actions across the theme

4.2 Responding to EU policy needs

Activity 4 Actions across the theme

4.1 – CSAs across the theme4.1-1 –Supporting industrial participation in EU-funded research in the Health sector.

Funding scheme:CA, max. €2m/project, up to one project

4.1-2 – Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation. Funding scheme:SA, max. €0.5m/project, one or more projects


4.1 – CSAs across the theme4.1-3 - Support for Presidency events. Organisation of supporting

actions and events associated to the Presidency of the European Union

"…specifically from mid-2013 to 2015 Presidencies, …"

Funding scheme:SA, max. €0.1m/project, one or more projects

4.1-4 - Preparing the future for health research and innovation.

Funding scheme:SA, max. €0.5m/project, one or more projects

4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations.


4.1-6: Mapping chronic non-communicable diseases research activities



4.2 – Responding to EU policy needs4.2-1 - Investigator-driven clinical trials for off-patent

medicines using innovative, age-appropriate formulations and/or delivery systems.


Industry topic: min. 30% EC contribution to industry, incl. SMEs.

4.2-2 - Adverse drug reaction research.


SME topic: min. 15 % EC contribution to SMEs.

4.2-3 - New methodologies for clinical trials for small population groups.


Ethics: overview (1)

• Two main questions asked on ethics:

The necessity to use i.e. personal data, animals, human tissue in order to achieve the scientific objectives set forth in the proposal. Is there an alternative ?

Benefit/burden balance of the research project. What will be the impact of this research, not only regarding scientific advance, but also in terms of human dignity as well as social and cultural impact ?

All proposals must address these questions.

Ethics: overview (2)• Applicants must first identify key ethical issues raised by their proposals

and explain how they will address them. The main issues are:– Informed Consent– Research on Human embryos/foetuses– Data Protection and Privacy– Research on Animals (the ‘3Rs’: Reduce, Replace, Refine)– Research involving Developing Countries– Dual use (research that could have military applications)

3 areas are excluded from funding:- Human reproductive cloning- Intentional germ line modification (except research relating to cancer of the gonads which can be funded)- Creation of human embryos for research or stem cell procurement (including by means of somatic cell nuclear transfer)

5. Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH…

Other funding opportunities for health research within the Cooperation Specific Programme

Call 7(WP2013)

• Research and Innovation for the benefit of society, with a challenges driven approach to maximize the impact of research funded by the EU

• 4 main challenges: the main pillars of bio-economySustainable

1) Agriculture and Forestry2) Safe and Sustainable Food and Health Diets3) Unlocking the potential of Aquatic Living Resources4) Sustainable and Competitive Bio-based Industries

• Broader topics in terms of budget and research developed, leaving greater freedom to the research community

Other funding opportunities for health research within the KBBE theme - 2013

Call identifier: FP7-KBBE-2013-7Proposal submission and evaluation: one-stage procedure. Date of publication: 10 July 2012Deadline for stage 1 proposals: 5 February 2013 at 17:00 (Brussels local time)Indicative budget: EUR 680 million from the 2013 [email protected] – [email protected]

mailto:[email protected]

mailto:[email protected]

Area 2.2.1 – Consumers

Impact of food and nutritional behaviour, lifestyle and the socio-economic environment on depression and proposed remedial actions (LCP, Up to one project )

Area 2.2.2 -NutritionNew technologies to study brain function in relation to eating behaviours and mental well-being (LCP, Up to one project )

Factors influencing the human gut microbiome and its effect on the development of diet related diseases and brain development (LCP, Up to one project )

KBBE topics

KBBE.2013.2.1-01: Impact of food and nutritional behaviour, lifestyle and the socioeconomic environment on depression and proposed remedial actions (Max 1 CP-IP. Max EC contribution: 6 M€)

KBBE.2013.2.2-01: New technologies to study brain function in relation to eating Behaviour (Max 1 CP-IP. Max EC contribution: 9 M€)

KBBE.2013.2.2-02: Factors influencing the human gut microbiome and its effect on the development of diet-related diseases and brain development (Max 1 CP-IP. Max EC contribution: 9 M€)

KBBE.2013.2.2-03: Food-based solutions for eradication of vitamin D deficiency and health promotion throughout the life cycle (Max 1 CP-IP. Max EC contribution: 6 M€)

Other funding opportunities for health research within the ICT theme - 2013

WP2013 will support the European Innovation Partnerships on Active and Healthy Ageing (EIP AHA) on Personalized health, active ageing, and independent living

ICTs have a catalytic impact in three key areas:

Productivity and innovation, by facilitating creativity and management

Modernisation of public services, such as health, education and transport.

Advances in science and technology, by supporting cooperation and access to information.

APERTURA DEADLINE

FP7-ICT-2013-10 10 Luglio 2012 15 Gennaio 2013 (734M€ from budget 2013)

FP7-ICT-2013-11 18 Settembre 2012 16 Aprile 2013 (242M€ from budget 2013)

FP7-2013-NMP-ICT-FoF 10 Luglio 2012 4 Dicembre 2012 (70M€ from budget 2013)

FP7-2013-NMP-ENV-ENERGY-ICT-EeB

10 Luglio 2012 4 December 2012 (40M€ from budget 2013)

FP7-2013-ICT-GC 10 Luglio 2012 4 December 2012 (40M€ from budget 2013)

FP7-ICT-2013-SME-DCA 10 Luglio 2012 15 Gennaio 2013 (20M€ from budget 2013)

FP7-ICT-2013-FET-F 10 Luglio 2012 23 Ottobre 2012 (100M€ from budget 2013)

FP7-ICT-2013-C 10 Luglio 2012 12 Marzo 2013 (50M€ from budget 2013)

FP7-ICT-2013-X 12 Settembre 2012 29 Gennaio 2013 (15M€ from budget 2013)

FP7-ICT2013-EU-Japan 2 Ottobre 2012 29 Novembre 2012 (9M€ from budget 2013)

FP7-ICT2013-EU-Brasil 10 Luglio 2012 24 Ottobre 2012 (4M€ from budget 2013)

BUDGET 1455 € [email protected] [email protected]

Challenge 5: ICT for Health, Ageing Well, Inclusion and Governance:

Personalized health, active ageing, and independent living

- Personalized Guidance Services for lifestyle management and disease prevention.- Personalized Guidance Services for management of co-morbidities and integrated care.- Personalized Services for Independent Living and Active Ageing.- Coordination and Support Actions.

Virtual Physiological Human Clinical proof of concept of patient specific computer based models

-Personal Health Forecasting.- Coordination and Support Action to develop an RTD roadmap preparing the ground for in-silico clinical trials

ICT for smart and personalised inclusion

- Accessible and intuitive solutions for personalised interfaces to smart environments and innovative services.- Coordination and Support Actions.

Other funding opportunities for health research within the NMP theme - 2013

Work Programme 2013 Priorities [email protected];[email protected]

• PPPs (Green Cars, Factories of the Future Energy Efficient Buildings): ~ 36%• Cross cutting innovation : ~12%• Application-specific innovation : ~26%• Raw Materials: ~3%• Energy : ~5%• Environment/Sustainability: ~9%• Health and safety: ~9%

NMP.2013.1.2-2 Nanotherapeutics to treat bacterial infectious diseases

NMP.2013.2.2-1 Biomaterials for Advanced Therapies and Medical Devices in the neurological/neuromuscular or cardiovascular fields

NMP.2013.2.2-2 Biomaterials: Imaging and rapid precise prototyping technology for custom made scaffolds – coordinated call with China

Other funding opportunities for health research within the ENV theme - 2013

CHALLENGE 6.4 PROTECTING CITIZENS FROM ENVIRONMENTAL HAZARDS

ENV.2013.6.4-1 Assessing individual exposure to environmental stressors and predicting health outcomes: paving the way for an EU-wide assessment (CP, Up to one project )

ENV.2013.6.4-2 Closing gaps of knowledge and reducing exposure to electromagnetic fields (EMF) (CP, Up to one project )

Call identifier: FP7-ENV-2013-two stageProposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 16 October 2012 at 17:00:00 (Brussels local time) Indicative budget: EUR 335.51 million from the 2013 [email protected]; [email protected]

Other funding opportunities for health research within the SSH theme - 2013

Draft Work Programme 2013:

SSH.2013.1.3-1 The impact of ageing societies on public finances in Europe Health care,

SSH.2013.3.2-2. Early childhood education and care and the cost of inequities

SSH.2013.3.2-3. The impact of the third sector on socio-economic development in Europe

Call identifier: FP7-SSH-2013-2Proposal submission and evaluation: one-stage procedure. Date of publication: 12 July 2012Deadline for stage 1 proposals: 31 January 2013 at 17.00.00 Brussels local timeIndicative budget: EUR 72 000000

[email protected]; [email protected]

Other funding opportunities for health research within the SPACE theme - 2013

Research and development on next generation products and service lines derived from space-borne data in conjunction with in-situ data is to be targeted

Activities could target applications on areas like:

Health services, or monitoring conditions for vector borne diseases (…)

Call identifier: FP7-SPACE-2013-1Proposal submission and evaluation: one-stage procedure. Date of publication: 12 July 2012 Deadline: 21 November 2012, at 17.00.00, Brussels local timeIndicative budget: EUR 126 [email protected]

Earth-analogue research preparing for space exploration

6. Other EU funding opportunities for Health researchers

7. Sources of information and partners

www.HealthCompetence.euAn open, pan-European infrastructure for information on research projects & results within Health Science

http:

//w

ww

.hea

lthnc

pnet

.eu

[FIND A PARTNER][FIND A PARTNER]

Pagina Salute, Sito APREwww.apre.it/ricerca-europea/VIIPQ/Cooperazione/Salute/Bandi.htm

CORDIS:CORDIS: http://cordis.europa.eu/fp7/health/

Fitforhealth: www.fitforhealth.eu

Healthncpnet: www.healthncpnet.eu

Healthcompentence: http://www.healthcompetence.eu/converis/publicweb/area/1353

PRESENTAZIONE IN 2 STAGE

4. Key issues for success

Basics Eligibility issues

- funding scheme, number of partners (esp. for SICA), funding limits, deadlines

Scope of proposal with respects to topic (Relevance) “The topic, the whole topic and nothing but the topic ” also pay attention to introduction in work programme and any specific requirements for industry or international participation

Size and composition of the consortium- beyond the minimum rules, there are no constraints: bring together the competences needed to do the job.

Advice for submission & evaluation (1)

No bonus points for “political correctness” or large consortia

Basics Address all 3 criteria – be explicit to evaluators

Address the Ethics issuesClear requirements for information on ethics issues* - you must explain what the issues are in the proposal- and how will you manage them

Failing to do so can delay negotiation or even exclude a proposal.

Respect basic rules and guidelines- font size (legibility) and page number limitations (excess pages will not be considered in the evaluation)

*Guide for Applicants, Annex 4, section 4.

Advice for submission & evaluation (2)

Competition is tough : only the best projects get funded

the proposal must address the topic and the work programme (not wishful thinking)

the consortium of partners must be excellent and competent for the tasks (select the right partners)

the proposal must address all 3 criteria,

convince the evaluators (don’t rely on reputation)

and, of course, respect the basic rules.(deadlines, n° of participants, ceilings, length, ethics…)

Key factors for success in applying for FP7 funding

Thanks for your attention !

Health NCP for ITALYAPRE,

Agenzia per la promozione della Ricerca Europea

Via Cavour 71, Roma

[email protected]; [email protected]

APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact...

Documents

Transcript of APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact...